Results 121 to 130 of about 164,371 (301)

Weakening the nuclear envelope: Lamin B receptor in melanoma metastasis

Molecular Oncology, EarlyView.
LBR‐driven nuclear fragility supports melanoma invasion. A: Melanocyte presents low LBR (Lamin B Receptor) levels, maintaining nuclear integrity and lamina‐chromatin tethering. B: During malignant progression, upregulation of LBR clusters at the INM (Inner Nuclear Membrane) during confined migration causes local lamina weakening and cholesterol ...
Francesca Lorenzini, Maria Caterina Mione   +1 more
wiley   +1 more source

Complexity of Delivering Precision Medicine: Opportunities and Challenges

, 2018
Precision medicine has emerged as a tool to match patients with the appropriate treatment based on the precise molecular features of an individual patient’s tumor.
Villaflor, Victoria M, Amy E. McKee, Davis, Andrew A, McKee, Amy E, Andrew A. Davis, Kibbe, Warren A, Victoria M. Villaflor, Warren A. Kibbe   +7 more
core   +1 more source

Liquid Biopsy: A Biomarker-Driven Tool towards Precision Oncology

, 2020
Liquid biopsy or the sampling of bodily fluids, mostly blood, has been intensely investigated and developed for clinical utility in medicine, especially oncology [...
Nelson S. Yee
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Expanding opportunities in precision oncology

Cancer Research, Statistics, and Treatment, 2020
T Raja
doaj   +1 more source

Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib

Frontiers in Oncology
BackgroundMetastatic colon adenocarcinoma presents significant challenges in treatment, particularly when resistant to standard therapies. Precision oncology, guided by multidisciplinary tumor boards (MTBs), offers a promising way for individualized ...
Esranur Aydın, Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Eylül Özgü, Şevval Nur Bilgiç, Mutlu Demiray   +6 more
doaj   +1 more source

OncoKB: A Precision Oncology Knowledge Base

, 2017
Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and ...
Martin H. Voss, Nikolaus Schultz, Neerav Shukla, Marc Ladanyi, Ritika Kundra, Shrujal S. Baxi, Maeve Lowery, José Baselga, Tiffany A. Traina, Rona Yaeger, Daniel C. Danila, Gopa Iyer, Margaret K. Callahan, Barry S. Taylor, Jiaojiao Wang, Ahmet Zehir, Ping Chi, Alexandra Snyder, James J. Harding, Sarat Chandarlapaty, Paul Sabbatini, Dana Rathkopf, David M. Hyman, Julia E. Rudolph, Matthew T. Chang, Matthew D. Hellmann, Gregory J. Riely, Moriah H. Nissan, Alan L. Ho, Douglas A. Levine, Paul K. Paik, Alexander N. Shoushtari, Hongxin Zhang, Feras M. Hantash, Antonio Omuro, Debyani Chakravarty, Andrew Grupe, Mrinal Gounder, Leonard B. Saltz, Ederlinda Paraiso, Thomas Kaley, Michael F. Berger, Jianjiong Gao, Michael A. Postow, David B. Solit, Sarah Phillips, Tara Soumerai, Yelena Y. Janjigian   +47 more
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics

, 2016
In early 2015 the National Institutes of Health launched a new, national Precision Medicine Initiative with the primary goal of rapidly improving the prevention, diagnosis, and treatment of cancers.
Fiore, Robin N, Goodman, Kenneth W
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source